Molecular Prognostic Prediction for Locally Advanced Nasopharyngeal Carcinoma by Support Vector Machine Integrated Approach

Background Accurate prognostication of locally advanced nasopharyngeal carcinoma (NPC) will benefit patients for tailored therapy. Here, we addressed this issue by developing a mathematical algorithm based on support vector machine (SVM) through integrating the expression levels of multi-biomarkers. Methodology/Principal Findings Ninety-seven locally advanced NPC patients in a randomized controlled trial (RCT), consisting of 48 cases serving as training set and 49 cases as testing set of SVM models, with 5-year follow-up were studied. We designed SVM models by selecting the variables from 38 tissue molecular biomarkers, which represent 6 tumorigenesis signaling pathways, and 3 EBV-related serological biomarkers. We designed 3 SVM models to refine prognosis of NPC with 5-year follow-up. The SVM1 displayed highly predictive sensitivity (sensitivity, specificity were 88.0% and 81.9%, respectively) by integrating the expression of 7 molecular biomarkers. The SVM2 model showed highly predictive specificity (sensitivity, specificity were 84.0% and 94.5%, respectively) by grouping the expression level of 12 molecular biomarkers and 3 EBV-related serological biomarkers. The SVM3 model, constructed by combination SVM1 with SVM2, displayed a high predictive capacity (sensitivity, specificity were 88.0% and 90.3%, respectively). We found that 3 SVM models had strong power in classification of prognosis. Moreover, Cox multivariate regression analysis confirmed these 3 SVM models were all the significant independent prognostic model for overall survival in testing set and overall patients. Conclusions/Significance Our SVM prognostic models designed in the RCT displayed strong power in refining patient prognosis for locally advanced NPC, potentially directing future target therapy against the related signaling pathways.

[1]  Billie Anderson,et al.  Comparison of the predictive qualities of three prognostic models of colorectal cancer. , 2010, Frontiers in bioscience.

[2]  Jian-ming Li,et al.  Over-expression of Nanog predicts tumor progression and poor prognosis in colorectal cancer , 2010, Cancer biology & therapy.

[3]  Jordi Giralt,et al.  Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. , 2010, The Lancet. Oncology.

[4]  Zlatko Trajanoski,et al.  In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  R. Sun,et al.  Induction-concurrent chemoradiotherapy versus induction chemotherapy and radiotherapy for locoregionally advanced nasopharyngeal carcinoma. , 2009, Ai zheng = Aizheng = Chinese journal of cancer.

[6]  Ruth Ladenstein,et al.  Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. , 2009, The Lancet. Oncology.

[7]  I. Wistuba,et al.  Phase II randomized study of biomarker-directed treatment for non-small cell lung cancer (NSCLC): The BATTLE (Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination) clinical trial program. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  B. Teh,et al.  Complexity of tumor vasculature in clear cell renal cell carcinoma , 2009, Cancer.

[9]  H. Wada,et al.  D2-40-Positive Lymphatic Vessel Density Is a Poor Prognostic Factor in Squamous Cell Carcinoma of the Lung , 2009, Annals of Surgical Oncology.

[10]  Christophe Lemetre,et al.  An introduction to artificial neural networks in bioinformatics - application to complex microarray and mass spectrometry datasets in cancer studies , 2008, Briefings Bioinform..

[11]  Jie Xu,et al.  Inhibition of Aurora-A suppresses epithelial-mesenchymal transition and invasion by downregulating MAPK in nasopharyngeal carcinoma cells. , 2008, Carcinogenesis.

[12]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[13]  J. Tang,et al.  Evaluation of Epstein-Barr virus antigen-based immunoassays for serological diagnosis of nasopharyngeal carcinoma. , 2007, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[14]  Andrew Kusiak,et al.  Cancer gene search with data-mining and genetic algorithms , 2007, Comput. Biol. Medicine.

[15]  Jeremy J. W. Chen,et al.  A five-gene signature and clinical outcome in non-small-cell lung cancer. , 2007, The New England journal of medicine.

[16]  W. Cho,et al.  Nasopharyngeal carcinoma: molecular biomarker discovery and progress , 2007, Molecular Cancer.

[17]  S. Mukherjee,et al.  A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. , 2006, The New England journal of medicine.

[18]  J. Grandis,et al.  Epidermal growth factor receptor biology in head and neck cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  W. Sauerbrei,et al.  Reporting recommendations for tumor marker prognostic studies (REMARK). , 2005, Journal of the National Cancer Institute.

[20]  Jun Ma,et al.  Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: A pooled data analysis of two phase III trials. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Russ Wolfinger,et al.  Generalizable mass spectrometry mining used to identify disease state biomarkers from blood serum , 2003, Proteomics.

[22]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[23]  Zong Yong Study on the Role of Epstein-Barr Virus Playing in Nasopharyngeal Carcinogenesis , 2002 .

[24]  O. Kallioniemi,et al.  Tissue microarrays (TMAs) for high‐throughput molecular pathology research , 2001, International journal of cancer.

[25]  V. Vapnik,et al.  Bounds on Error Expectation for Support Vector Machines , 2000, Neural Computation.

[26]  Jun Ma,et al.  A comparison of the Chinese 1992 and fifth‐edition International Union Against Cancer staging systems for staging nasopharyngeal carcinoma , 2000, Cancer.

[27]  R. Day,et al.  Levels of TGF-α and EGFR Protein in Head and Neck Squamous Cell Carcinoma and Patient Survival , 1998 .

[28]  R. Day,et al.  Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. , 1998, Journal of the National Cancer Institute.

[29]  W. Enker,et al.  Combined modality therapy of rectal cancer: decreased acute toxicity with the preoperative approach. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Pelayo Vilar,et al.  Nasopharyngeal Carcinoma , 1966 .